Literature DB >> 2106113

Comparative study of the sensitivity of head and neck cell lines to methotrexate (MTX) and the analog 10-ethyl, 10-deazaaminopterin (10-EdAM).

D H Brown1, B J Braakhuis, G A Van Dongen, G B Snow.   

Abstract

Squamous cell lines cultured in vitro provide a potential test system for the selection of analogs that have an improved therapeutic index. The growth inhibitory effects of methotrexate and the new folate analog 10-ethyl, 10-deazaaminopterin were compared in three in vitro-cultured human head and neck squamous cell carcinoma cell lines. The inhibitory concentrations of the new analog were 10- to 100-fold lower than the inhibitory concentrations of methotrexate. The sensitivity of these three head and neck squamous cell carcinoma cell lines to both drugs was essentially the same as the sensitivity of a rhabdomyosarcoma cell line known to be very sensitive to methotrexate when the cell line is grown as a xenograft in athymic nude mice. These data indicate that 10-ethyl, 10-deazaaminopterin may be a new and effective agent against head and neck squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2106113     DOI: 10.1177/019459989010200104

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  2 in total

1.  Phase II study of edatrexate in advanced head and neck cancer. A Southwest Oncology Group study.

Authors:  J P Kuebler; J Benedetti; D E Schuller; J Ensley; S M Grunberg; M J Muirhead; K E Richert-Boe; M E Marshall
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

2.  Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neck.

Authors:  M H Huber; I W Dimery; S E Benner; S M Lippman; M Shirinian; B Esparaz; D Frenning; C Guillory-Perez; W K Hong
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.